Introduction {#s1}
============

Chronic kidney disease (CKD) is a current public health problem associated with progression to end-stage renal disease (ESRD), cardiovascular disease and increased mortality rates. The disease has a progressive course, and it is estimated that for every patient on renal replacement therapy (RRT) there are 20--25 patients with milder kidney damage \[[@SFV099C1]\].

The risk of cardiovascular events increases proportionally with the decline of glomerular filtration, reaching rates 10--20 times higher than in the general population among ESRD patients \[[@SFV099C1]\]. The mortality rate of CKD patients is 15--30 times higher than that of healthy individuals. The disease is also associated with greater health expenditures \[[@SFV099C2]\] and lower health-related quality of life (HRQOL) \[[@SFV099C3]\].

Physical activity is one of the key elements for the prevention of chronic diseases. Among the general population, physical activity reduces the risk of complex chronic diseases, particularly ischemic heart disease, contributes to blood pressure and glucose control and improves the HRQOL \[[@SFV099C3]\].

The prescription of exercise for CKD patients is less usual than for other chronic diseases. This is noteworthy, considering that physical activity levels among CKD patients are significantly lower than among healthy individuals \[[@SFV099C4]\]. Moreover, low aerobic capacity, a physical fitness marker that can be improved by exercise, has been pointed to as the strongest predictor of mortality among ESRD patients \[[@SFV099C5]\]. Assuming that the benefits of exercise could also apply to CKD patients, physical activity deserves to be considered as a major component of treatment in all stages of the disease \[[@SFV099C4]\].

In order to critically appraise the evidence currently available on the issue, we conducted a systematic literature review on the effectiveness of exercise interventions among CKD patients.

Methods {#s2}
=======

The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) statement for the conduct of meta-analyses of intervention studies was followed \[[@SFV099C6]\].

Eligibility criteria were randomized controlled trials (RCT) evaluating any type of exercise intervention, including advising for physical activity practice, in CKD patients, regardless of their disease stage. The studies based on the same sample, but with different outcomes were included. Only studies with adults (≥18 years) were selected.

Studies on the acute effects of exercise (intervention lasting \<8 weeks) and/or quasi-experimental studies were excluded.

Literature search {#s2a}
-----------------

A search for articles up to and including June 2015 was made from MEDLINE (accessed via PubMed) and EMBASE; we combined these search results with searches of the Cochrane Central Register, and clinical trials registry databases. Conference proceedings abstracts also were hand searched (American Society of Nephrology from 2003 to 2014, European Renal Association--European Dialysis and Transplant Association from 2002 to 2014 and World Congress of Nephrology from 2001 to 2012).

The initial search included terms such as 'exercise', 'physical activity', 'chronic renal disease' and related entry terms associated with a high-sensitivity strategy search. Most of the eligible studies were found on the PubMed database. By the specific search strategy used for the PubMed database, we used the following terms:

((((((((((exertion, physical\[MeSH Terms\]) OR exercise\[MeSH Terms\]) OR 'exercise therapy') OR physical activity\[MeSH Terms\]) OR physical fitness\[MeSH Terms\]) OR resistance training\[MeSH Terms\]) OR aerobic exercise\[MeSH Terms\]) OR exercise\[MeSH Terms\])) OR (((((((((((((((((exercise) OR 'exercise training') OR 'physical activity') OR 'aerobic exercise') OR 'aerobic training') OR 'resistance program') OR 'resistance exercise') OR 'resistance training') OR 'aerobic program') OR 'endurance exercise') OR 'endurance training') OR 'endurance program') OR 'physical activity') OR 'physical activities') OR 'exercise therapy') OR 'exercise test') OR 'physical rehabilitation'))).

(((((((((((((renal dialysis\[MeSH Terms\]) OR uremia\[MeSH Terms\]) OR renal replacement therapy\[MeSH Terms\]) OR hemodialysis\[MeSH Terms\]) OR hemodialyses\[MeSH Terms\]) OR dialysis\[MeSH Terms\]) OR chronic kidney failure\[MeSH Terms\]) OR renal insufficiency\[MeSH Terms\]) OR kidney failure\[MeSH Terms\]) OR kidney transplantation\[MeSH Terms\]) OR dialyses\[MeSH Terms\])) OR ((((((((((((uremia) OR 'renal replacement therapy') OR hemodialysis) OR hemodialyses) OR dialysis) OR dialyses) OR 'chronic kidney failure') OR 'chronic kidney disease') OR 'renal insufficiency') OR 'kidney failure') OR 'renal disease') OR 'kidney transplantation')).

Data extraction {#s2b}
---------------

The articles identified in the literature search were screened by two independent extractors (F.C.B and M.B) who were blinded to authorship. The initial screening was based on only titles and abstracts. After that, the full text of potentially eligible articles was evaluated. Data extraction of selected RCTs was performed by two independent reviewers (F.C.B and M.B). Discrepancies between the two extractors were discussed until consensus was reached.

Outcome measures {#s2c}
----------------

This review focused on clinically relevant outcomes, measured using physiological and psychological variables associated with progression and complications of CKD.

Primary outcomes: Physical fitness: aerobic capacity, muscular strength;Health-related quality of life (measured through well-established, reliable and validated instruments);Cardiovascular dimensions: heart rate variability (HRV) index, mean RR, mean standard deviation of normal-to-normal intervals (SDNN), pulse wave velocity (PWV) and arterial stiffness;Nutritional measures: body composition (visceral fat, waist circumference and leg lean mass), body mass index, waist circumference);Depression;Systemic inflammation: interleukin 6, C-reactive protein.Secondary outcomes: Blood lipids: total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides;Progression of CKD: determined as glomerular filtration from serum creatinine and/or cystatin C and/or radioisotope tracing.

Assessment of risk of bias {#s2d}
--------------------------

Reviewers (F.C.B and M.B) independently assessed the risk of bias of included studies using the Cochrane Collaboration\'s tool \[[@SFV099C7]\]. The quality of RCTs was judged by selection bias (method of recruitment, proper method of randomization at baseline, concealment of treatment allocation, similarity of groups at baseline and provision of eligibility criteria), detection bias (use of masked outcome assessment, blinded administrator and blinded patients) and attrition bias (level of adherence to the intervention, completeness of follow-up and use of intention-to-treat analysis). Any disagreement concerning data extraction and/or quality was resolved in a consensus meeting.

Each item was rated by assigning a judgment of high, low or unclear risk of material bias. We define material bias as bias of sufficient magnitude to have a notable effect on the results or conclusions of the trial, recognizing the subjectivity of any such judgment.

Results {#s3}
=======

Literature search {#s3a}
-----------------

We retrieved 5489 articles in searches from inception through June 2015 from MEDLINE, EMBASE, PubMed, Cochrane Central, clinical trials registries, and nephrology conference proceedings. Initially 486 duplicated articles were excluded. Of the 5003 articles examined for eligibility, 4861 were excluded based on the title or abstract. The full texts of 142 potentially eligible studies were evaluated. Of these, 59 fulfilled inclusion criteria and were included in the review (Figure[ 1](#SFV099F1){ref-type="fig"}). Fig. 1.Exercise interventions in chronic renal disease patients: literature search results.

### Selected trials {#s3a1}

Table [1](#SFV099TB1){ref-type="table"} describes the studies in terms of sample size, type and duration of intervention, CKD stage, main outcome measures and results. Fifty-nine studies, randomizing 2858 participants, were identified and selected for this review. The number of participants was usually small, ranging from 11 \[[@SFV099C23]\] to 297 \[[@SFV099C42]\] subjects, the last being a multicenter study. In 38 studies (67%), the sample size was \<50 participants \[[@SFV099C8]--[@SFV099C10], [@SFV099C12]--[@SFV099C19], [@SFV099C21]--[@SFV099C26], [@SFV099C28]--[@SFV099C30], [@SFV099C35], [@SFV099C37]--[@SFV099C41], [@SFV099C45]--[@SFV099C47], [@SFV099C49], [@SFV099C50], [@SFV099C52], [@SFV099C53], [@SFV099C55]--[@SFV099C58], [@SFV099C60]\]. Only three studies used a healthy control group \[[@SFV099C61], [@SFV099C51], [@SFV099C62]\] in addition to a CKD control group. Most interventions lasted from 8 to 24 weeks; six trials lasted ≥1 year \[[@SFV099C26], [@SFV099C31]--[@SFV099C33], [@SFV099C43], [@SFV099C63]\]. Only one study compared exercise advice and rehabilitation counseling for pre-dialysis and dialysis patients \[[@SFV099C22]\]. Table 1.Description of the studies on exercise interventions in CKD patientsAuthor, yearGroups (*n*)InterventionTime (weeks)CKD stageOutcome variablesMain results (refers to I group compared with C group)Afshar *et al*. (2010) \[[@SFV099C8]\]Ia = 7\
Ir = 7\
C = 7Ia: aerobic training\
Ir: resistance training\
C: usual care8HDBlood chemistry (urea, creatinine, lipids, CRP), Kt/V and anthropometric measureCRP and creatinine reduction in aerobic exercise (P = 0.005) and resistance (P = 0.036), no effect on weight, urea, lipids or Kt/VAkiba *et al*. (1995) \[[@SFV099C9]\]I = 10\
C = 10I: exercise training\
C: usual care12HDAerobic capacity (VO~2~ max, VO~2~AT)VO~2~ max (P \< 0.05) and VO~2~AT (P \< 0.05) were decreased in C group and unchanged in I groupBaria *et al*. (2014) \[[@SFV099C10]\]Ic = 10\
Ih = 8\
C = 9Ic: center aerobic\
Ih: home aerobic\
C: usual care12Obese PHBody composition, abdominal distribution of fatVisceral fat and waist circumference decreased 6.4 ± 6.4 mm (P \< 0.01) and 2.0 ± 2.3 cm (P = 0.03) and leg lean mass increased 0.5 ± 0.4 kg (P \< 0.01)Bohm *et al*. (2014) \[[@SFV099C11]\]Ic = 30\
Ip = 30Ic: cycle ergometer\
Ip: home-based walking24HDCapacity aerobic, strength lower, flexibility, accelerometer and HRQLNo significant differences in any outcomes were identified between interventions groupsCarmack *et al*. (1995) \[[@SFV099C12]\]I = 23\
I = 25I: aerobic training\
C: attention wait-list10HDVO~2~ peak, depressionSignificant improvement in aerobic capacity. There were no significant changes between groups on measures of depressionCastaneda *et al*. (2001) \[[@SFV099C13]\]I = 14\
C = 12I: low protein diet + resistance training\
C: low protein diet only12P-HDTBP, muscle fibers type I and II, GFRTBP, I and II fibers increased 4 ± 8%, 24 ± 31%, 22%; strength: I: 32 ± 14%; C: −13 ± 20% (P \< 0.001); ΔGFR I: 1.18; C: −1.62 (P = 0.048)Castaneda *et al*. (2004) \[[@SFV099C14]\]I = 14\
C = 12I: low protein diet + resistance training\
C: low protein diet only12P-HDCRP, IL-6, CSA of muscle fibers, muscle strengthCRP (−1.7 mg/L; P = 0.01), IL-6 (−4.2 pg/mL; P = 0.01) decreased, type I (24 ± 31%), type II (22 ± 41%) and strength (28 ± 14%; P = 0.001) increasedCheema *et al*. (2007) \[[@SFV099C15]\]I = 24\
C = 25I: intense resistance training\
C: usual care12HDMuscle CSA, lipid content and strength, CRP and quality of lifeMuscle strength (RR = 0.59; P = 0.04), body weight (RR = 0.62; P = 0.06) and CRP (RR = −0.63; 95% CI −0.54--0.00) improved; no change in muscle CSAChen (2010) \[[@SFV099C11]\]I = 25\
C = 25I: intradialytic low-intensity strength training\
C: stretching24HDSPPB, lower body strength, body composition and quality of lifeSPPB improved 21.1% (43.1%) in I versus 0.2% (38.4%) in C (P = 0.03); sensitivity analysis: SPPB correlated to knee extensor strength (*r* = 0.33)Deligiannis *et al*. (1999) \[[@SFV099C16]\]I~Hd~ = 30\
C~Hd~ = 30\
C~S~ = 30I~Hd~: supervised training 3×/w non-dialysis\
C~Hd~ and C~s~: usual care28HDHRV, SDNN, VO~2~ maxHRV increased from 22 ± 7 to 28 ± 9 (P \< 0.05), SDNN from 0.11 ± 0.03 to 0.13 ± 0.04 (P \< 0.05), VO~2~ max by 41% and exercise testing duration by 33%Deligiannis (1999) \[[@SFV099C17]\]I~a~ = 16\
I~b~ = 10\
C~hd~ = 12\
C~s~ = 15I~a~: aerobic HD\
I~b~: aerobic at home\
C~hd~: HD controls\
C~s~: healthy controls28HDSpiroergometric echocardiographic\
HRpeak, VO max,\
pulmonary ventilationI~a~ and I~b~: increased exercise time 33%/17% and VO~2~ max 43%/14%; I~a~: increase in FE 5% and SVI 14%; unchanged in C~hd~DePaul *et al*. (2002) \[[@SFV099C18]\]I = 20\
C = 18I: resistance and aerobic\
C: range-of-motion exercises12HDSubmaximal workload, muscle strength, 6MWT, QOL, symptoms scoresIncreased on the submaximal exercise test and muscle strength, but not in 6MWT, symptoms questionnaire or quality of lifeDobsak *et al*. (2012) \[[@SFV099C19]\]Iet = 11\
Iems = 11\
C = 10Iet: aerobic training\
Iems: electrostimulation\
C: usual care20HDWpeak, 6MWT, muscle power (Fmax), urea clearance and HRQOLSigniﬁcant improvement of Wpeak, Fmax and 6MWT in ET and EMS. No difference between ET and EMS groupsDong *et al*. (2011) \[[@SFV099C20]\]I = 33\
C = 33I: Resistance training plus nutrition\
C: nutrition alone24HDBody composition, muscle strength, biochemical parameters, recall dietaryNo difference in lean body mass. Weight and strength increased in I groupEidemak *et al*. (1997) \[[@SFV099C21]\]I = 15\
C = 15I: aerobic training\
C: usual care24P-HDVO~2~ max, BP, HR, serum lipids, GFRMaximal work capacity increased in the exercise group. No difference in ΔGFRFitts (1999) \[[@SFV099C22]\]PR = 9\
PC = 9\
DR = 9\
DC = 9R: exercise coaching\
C: usual lifestyle\
P: pre-dialysis\
D: hemodialysis.24P-HD and HD6MWT, HRQL, resting HRPR walked more. Hematocrit increased in R. Quality of life was stable or improved in PR, but declined in PC. PR benefited more than DRFrey (1999) \[[@SFV099C23]\]I = 6\
C = 5I: cycle 60--80% of maximal heart rate\
C: usual care12HDDietary recalls, prealbumin, transferrin and pre-dialysis and post-dialysis albuminNo increased visceral proteinsGiannaki *et al*. (2013) \[[@SFV099C24]\]I = 12\
C = 12I: aerobic training\
C: usual care26HD (RSL)Severity of RLS, functional capacity, sleep quality, depression levelsRLS severity decreased (P = 0.017), depression score (P = 0.002) and daily sleepiness (P = 0.05) improvedGiannaki *et al*. (2013) \[[@SFV099C25]\]I~E~ = 16\
I~da~ = 8\
C = 8I~E:~ aerobic training\
I~da:~ dopamine agonist\
C: usual care26HD (RSL)Severity of RLS, functional capacity, muscle quality, depression, sleep qualityRLS improved in groups exercise and dopamine agonist (P = 0.03) and only agonist group improved sleep score (P = 0.016)Goldberg *et al*. (1983) \[[@SFV099C26]\]I = 14\
C = 11I: aerobic training 3 to 5 times weekly\
C: usual care52 ± 4HDAerobic capacity, BP, lipids, Ht, weight, fasting plasma insulinIncreased aerobic capacity 21%, exercise stress test 19%, decrease in BP, plasma insulin 20%, TG 33%. Increase in HDL, HtGordon *et al*. (2012) \[[@SFV099C27]\]I = 33\
C = 33I: Hatha yoga exercise\
C: usual care16HDSerum total cholesterol, LDL, HDL and TGDecrease in TG, LDL and total cholesterol/HDL ratioGregory *et al*. (2011) \[[@SFV099C28]\]I = 14\
C = 11I: supervised exercise and dietary counseling\
C: usual care.48P-HDTreadmill testing, IGF-I, IGF-II, IGFBP-1No difference in the IGF system. Interaction between group and time for VO~2~ and total treadmill timeHeadley *et al*. (2012) \[[@SFV099C29]\]I = 14\
C = 11I: personal training and dietary counseling\
C: usual care48P-HDVO~2~ peak, eGFR, resting and ambulatory HR, lipids, CRP and IL-6Increase in VO~2~ peak from 18.1 ± 7.8 to 20.1 ± 7.3, reductions of HR, increases in LDL and TG, no effect in eGFRHeadley *et al*. (2014) \[[@SFV099C30]\]I = 25\
C = 21I: aerobic training\
C: usual care16P-HDArterial stiffness, aerobic capacity, endothelin1, nitrate/nitrite, CRP, HRQLNo change in arterial stiffness (PWV).\
8.2% increase in VO~2~ peak, physical function, vitality, bodily painHowden *et al*. (2013) \[[@SFV099C31]\]I = 41\
C = 42I: lifestyle and aerobic and resistance training\
C: usual care52P-HDPeak VO~2~, left ventricular function, arterial stiffness, anthropometric measuresImproved peak VO~2~ (P = 0.004), weight loss (P = 0.02), diastolic function (P = 0.001), arterial elastance (P = 0.01). No change in BPJohansen, (2006) \[[@SFV099C32]\]I~ex~ = 20\
I~ex/nd~ = 20\
I~nd~ = 19\
P = 20I~ex~: resistance training\
I~ex/nd~: exercisee + nd\
I~nd~: nandrolone\
P: placebo12HDBody composition (LBM), muscle size and strength, physical performance and activityLBM: nandrolone increased (P \< 0.0001), ex no effect. Quadriceps CSA increased in ex (P = 0.01) and nd (P \< 0.0001). Ex increased physical functioning (P = 0.04)Koh (2010) \[[@SFV099C33]\]I~Hd~ = 27\
I~Ho~ = 21\
C = 22I~Hd~: intradialytic cycle\
I~Ho~: home-based walking\
C: usual care24HD6MWT, PWV, augmentation index, physical activity, physical functioning.No differences between Δ6MWT (intra Hd +14%, home +11%, usual care +5%), PWV, or any secondary outcome measureKonstantinou (2002) \[[@SFV099C10]\]I~Ohd~ = 21\
I~Hd~ = 12\
I~Ho~ = 12\
C~Hd~ = 13\
Cs = 15I~Ohd~: outpatient training\
I~Hd~: during HD training\
I~Ho~: non-supervised home\
C~Hd~: HD controls\
Cs: healthy controls24HDVO~2~ peak, VO~2~AT, exercise time, dropout rateI~Ohd~: higher dropout; VO~2~ peak increased 43%, VO~2~ AT 37%, exercise time 33%\
I~Hd~: 24, 18 and 22%; I~Ho~: 17, 8, 14%; respectively. Intense exercise outpatient is the most effective trainingKopple *et al*. (2007) \[[@SFV099C34]\]Icve = 10\
Ires = 15\
Imix = 12\
C = 14Icve: aerobic training\
Ires: resistance training\
Imix: combined training\
C: usual care20HDMean body and fat mass, mid-thigh CSA, BMI, mRNA levels of growth factors genes in musclemRNA increased for IGF-IEa, IGF-IEc, IGF-IR, IGF-II, IGFBP-2, and IGFBP-3. No change in CRP, TNF, and IL-6 concentrationsKoufaki (2002) \[[@SFV099C35]\]I = 18\
C = 15I: aerobic cycle\
C: usual care12HD/CAPDFunctional capacity, 6MWT, VO~2~ peak, VO~2~ at ventilatory thresholdSignificantly improved peak exercise capacity 21.2 ± 7.2 to 26.9 ± 6.2 and C = 23.7 ± 6.8 to 24.1 ± 7.2Kouidi (2009) \[[@SFV099C36]\]I = 30\
C = 29I: combined training\
C: usual care42HDVO~2~ peak, FE, HR variabilityVO~2~ peak from 16.4 ± 5.4 to 21.4 ± 6.8 mL/kg/min and HRV increased 12.6 ± 16.3 (P \< 0.001)Kouidi *et al*. (2010) \[[@SFV099C37]\]I = 25\
C = 25I: HD cycling\
C: usual care52HDVO~2~ peak, VCO~2~/VO~2,~ depression (BDI and HADS), HRV (SDNN, LF/HF)VO~2~ peak increased 24%, exercise time 61.4%, LH/HF 17% and SDNN 59%. Decreased BDI 34.5% and HADS 23.5%Kouidi *et al*. (2013) \[[@SFV099C38]\]I = 12\
C = 12I: aerobic training\
C: usual care24TXHRV, arterial baroreflex sensitivityVO~2~ peak increased by 15.8% (P \< 0.05) and all depressed HRV and BRS indices were improved after trainingLeehey *et al*. (2009) \[[@SFV099C39]\]I = 7\
C = 6I: aerobic 6 weeks + 18 weeks home supervised\
C: usual care24P-HD + DM2VO~2~ max, exercise duration, GFR, Hb, HbA1, lipids, CRP and 24-h proteinuriaIncrease in exercise duration. No difference in GFR, Hb, HbA1, lipids, CRP or 24-h proteinuriade Lima *et al*. (2013) \[[@SFV099C40]\]Ia = 10\
Is = 11\
C = 11Ia: aerobic, bicycle\
Is: training load ankle\
C: usual care8HDRespiratory strength, lung function, functional capacity, biochemistry, HRQOLImprovement (P \< 0.05) in the maximal inspiratory pressure, number of steps achieved, and quality of lifeMakhlough *et al*. (2012) \[[@SFV099C41]\]I = 25\
C = 23I: aerobic training\
C: usual care8HDCalcium, phosphate, potassium, HbDecrease in serum phosphate (by 1.84 mg/dL) and potassium (0.69 mg/dL)Mallamaci *et al*. (2014) \[[@SFV099C42]\]I = 151\
C = 146I: home exercise program\
C: usual care24HD6MWT and Sit-to-Stand testIncreased 6MWT, 369 ± 113 to 324 ± 116 (P \< 0.001) and sit-to-stand 18.3 ± 19.7 ± 6.7 s between groupsMatsumoto *et al*. (2007) \[[@SFV099C43]\]I = 22\
C = 33I: exercise training\
C: usual care52HDAlbumin, HRQOL, creatinine generation (CGR)Serum albumin, CGR and HRQOL increased in the I groupMohseni *et al*. (2013) \[[@SFV099C44]\]I = 25\
C = 25I: aerobic training\
C: usual care8HDDialysis efficacy (Kt/v and URR)Increased intragroup URR (P = 0.003) and Kt/v (P = 0.001), between groups not statedMolsted *et al*. (2004) \[[@SFV099C45]\]I = 22\
C = 21I: aerobic training 2× week\
C: usual care20HDAerobic capacity, 2-min stair climbing, squat test, SF-36, BP and lipidsIncrease in aerobic capacity and Physical Summary Score (SF36)Mortazavi *et al*. (2013) \[[@SFV099C46]\]I = 13\
C = 13I: aerobic training 3× week\
C: usual care16HD\
RLSSeverity of RLS, HRQL (SF-63)Decreased scores of RLS and HRQL no difference between groupsOrcy *et al*. (2012) \[[@SFV099C38]\]I = 13\
C = 13I: resistance and aerobic\
C: resistance only10HDFunctional\
performance (6MWT)6MWT changed 39.7 ± 61.4 m in I group and −19.2 ± 53.9 m in C group (P = 0.02)Ouzouni *et al*. (2009) \[[@SFV099C47]\]I = 20\
C = 15I: resistance and aerobic\
C: usual care40HDVO~2~ peak, HRQOL, personality parametersIncreased VO~2~ peak (21.1%) and physical HRQOL, decreased depressionPainter *et al*. (2002a) \[[@SFV099C48]\]I~HtU~ = 10\
I~HtN~ = 12\
C~HtU~ = 14\
C~HtN~ = 12I: aerobic training\
C: usual care\
HtU: Ht 30--33%\
HtN: Ht 40--42%20HDTreadmill, VO~2~ peak\
HRQL (SF-36)I: increased VO~2~ peak (P = 0.03),\
physical functioning (P = 0.01); HtN: increased general health (P = 0.03)Painter *et al*. (2002b) \[[@SFV099C32]\]I = 54\
C = 43I: exercise at home\
C: usual care52TxSymptom-limited exercise, VO~2~ peak, isokinetic testing, body composition, SF-36Increased VO~2~ (24.0 ± 7.5 to 30.1 ± 10.3 mL/kg/min) and muscle strength. No differences in body composition or HRQLPainter (2003) \[[@SFV099C33]\]I = 51\
C = 45I: aerobic training\
C: usual care52TxMaximal exercise testing, risk factors, Framingham equationsIncrease in total cholesterol, HDL-C, and body mass index over time. No differences between groupsParsons (2004) \[[@SFV099C49]\]I = 6\
C = 7I: aerobic cycle\
C: usual care08HDSF-36, KtV, 2-h DUC, BP, and maximal work capacityOnly DUC in the first 2-h was higher in I groupPellizzaro *et al*. (2013) \[[@SFV099C50]\]RMT = 11\
PMT = 14\
C = 14RMT: inspiratory muscles\
PMT: knee extensor muscle\
C: usual care10HDRespiratory strength, functional capacity, HRQOL, inflammatory stateΔPI and ΔPE increased in RMT; Δ6MWT increased in RMT and PMT, CRP reduced and HRQOL increased in RMT and PMTPetraki *et al*. (2008) \[[@SFV099C51]\]I = 22\
C~HD~ = 21\
C~S~ = 20I: aerobic during HD\
C~HD~: HD controls\
C~s~: healthy controls28HDArterial baroreflex sensitivity, spiroergometric studyImprovement in VO~2~ peak, exercise time and arterial baroreflex sensitivityReboredo *et al*. (2010) \[[@SFV099C52]\]I = 11\
C = 11I: aerobic during HD\
C: usual care12HDHRV and LVF by Holter and echocardiography No differences in HRV or LVF between the groupsReboredo (2011) \[[@SFV099C53]\]I = 14\
C = 14I: aerobic during HD\
C: usual care12HDVO~2~ peak and time to exercise intolerance (Tlim)Training improved 50 to 200% in Tlim and VO~2~ peak in 15--20%Rossi *et al*. (2014) \[[@SFV099C54]\]I = 59\
C-48I: treadmill cardiovascular and weight training+usual C: usual care12P-HD6 MWT, sit-to-stand testIntervention significant: 6-MWT 19% improvement (P \< 0.001), sit-to-stand test 29% improvement (P \< 0.001)Segura-Ortí (2009) \[[@SFV099C55]\]I~RT~ = 19\
I~LA~ = 8I~RT~: resistance during HD.\
I~LA~: aerobic24HDAerobic capacity, muscle strength, HRQOLI~RT~ improved right knee extensor muscles strength. No difference in physical testsSong and Sohng (2012) \[[@SFV099C56]\]I = 20\
C = 20I: resistance training\
C: usual care12HDBody composition, physical fitness, HRQOL, lipid profileMuscle strength and HRQOL increased, cholesterol and triglyceride decreasedToussaint (2008) \[[@SFV099C57]\]I = 9\
C = 10I: aerobic cycle (cross-over)\
C = usual care12HDPWV, measurements of BNPPWPV improved, BNP decreasedTsuyuki *et al*. (2003) \[[@SFV099C58]\]I = 17\
C = 12I: aerobic exercise HD\
C: usual care20HDVO~2~ peak, BP, oxygen uptake efficiency slope (OUES)OUES increased in physical training group, no change in control groupvan Vilsteren (2005) \[[@SFV099C59]\]I = 60\
C = 43I: resistance before and aerobic during HD\
C: usual care12HDKt/V, Ht, cholesterol, BP, weight, physical fitness, SF-36, behaviorImprovement in behavior, reaction time, lower extremity muscle strength, KtV and quality of lifeWilund *et al*. (2010) \[[@SFV099C60]\]I = 8\
C = 9I: aerobic training\
C: usual care16HDWalk test, cholesterol, OS, CRP, IL-6, K, P, Ca, ALP, urea, albumin, heart functionWalk increased 17%, OS and epicardial fat reduced. No change in CRP, IL-6 or other variablesYurtkuran (2007) \[[@SFV099C17]\]I = 19\
C = 18I: yoga-based exercises\
C: usual care12HDVisual analogue scale (pain, fatigue, sleep), grip strength, biochemical variablesImprovement in pain −37%, fatigue −55%, sleep disturbance −25%, strength +15%, Ht +13%, creatinine −14%, cholesterol −15%[^1]

Twenty-eight of the 59 studies were published after 2009 (Table [1](#SFV099TB1){ref-type="table"}). Despite the fact that diabetes and hypertension are the main comorbidities associated to CKD, only one study was restricted to diabetic CKD \[[@SFV099C39]\] and one to obese pre-dialysis patients \[[@SFV099C10]\].

Assessment of the quality of studies {#s3b}
------------------------------------

Results of the risk of bias assessment are presented in Figure[ 2](#SFV099F2){ref-type="fig"}. Risks of bias due to blinding and incomplete outcome data were assessed across all outcomes within each included study. Fig. 2.Risk of bias assessments of RCTs on the effectiveness of exercise interventions among CKD patients.

### Selection bias {#s3b1}

*Allocation*: The most frequently detected shortcomings were related to randomization and generation of the allocation sequence. Only 23 studies had adequate randomization \[[@SFV099C13], [@SFV099C15], [@SFV099C17], [@SFV099C18], [@SFV099C24], [@SFV099C25], [@SFV099C31]--[@SFV099C33], [@SFV099C35]--[@SFV099C37], [@SFV099C39], [@SFV099C44], [@SFV099C45], [@SFV099C48], [@SFV099C50], [@SFV099C54], [@SFV099C55], [@SFV099C64]--[@SFV099C67]\] and concealment of the allocation sequence was described in only 14 RCTs \[[@SFV099C11], [@SFV099C15], [@SFV099C17], [@SFV099C18], [@SFV099C25], [@SFV099C31]--[@SFV099C33], [@SFV099C35]--[@SFV099C37], [@SFV099C45], [@SFV099C55], [@SFV099C65]\].

### Detection bias {#s3b2}

*Blinding*: The blinding process of participants, care providers and assessors was described in six studies \[[@SFV099C18], [@SFV099C32], [@SFV099C33], [@SFV099C45], [@SFV099C55], [@SFV099C59]\]. Only three studies used blinding of the outcomes \[[@SFV099C18], [@SFV099C44], [@SFV099C60]\].

### Attrition bias {#s3b3}

*Dropout rates*: Forty-one of 59 studies reported dropout rates. Thirty-two had a dropout rate between 0 and 30% \[[@SFV099C10], [@SFV099C11], [@SFV099C13], [@SFV099C14], [@SFV099C16]--[@SFV099C18], [@SFV099C20]--[@SFV099C25], [@SFV099C29], [@SFV099C32], [@SFV099C33], [@SFV099C36], [@SFV099C39], [@SFV099C43], [@SFV099C47], [@SFV099C49], [@SFV099C55], [@SFV099C57], [@SFV099C58], [@SFV099C61]--[@SFV099C66], [@SFV099C68]\]. One study \[[@SFV099C12]\] had a dropout rate \>70%.

*Intention-to-treat analysis*: The analysis was conducted according to the intention-to-treat principle in only 10 studies \[[@SFV099C10], [@SFV099C13], [@SFV099C16], [@SFV099C18], [@SFV099C21], [@SFV099C24], [@SFV099C32], [@SFV099C33], [@SFV099C54], [@SFV099C67]\].

*Adherence to interventions*: Only nine RCTs reported on compliance, which was computed as the number of sessions attended out of the total possible sessions, expressed as a percentage \[[@SFV099C11], [@SFV099C15], [@SFV099C31], [@SFV099C38], [@SFV099C56], [@SFV099C64], [@SFV099C65], [@SFV099C67], [@SFV099C69]\]. The compliance ranged from 70 \[[@SFV099C31]\] to 89% \[[@SFV099C11], [@SFV099C65]\].

### Other quality indicators {#s3b4}

Sample size calculations were not consistently presented in the articles, making it difficult to interpret whether non-significant findings were due to insufficient study power in eight studies \[[@SFV099C16], [@SFV099C18], [@SFV099C21], [@SFV099C24], [@SFV099C32], [@SFV099C33], [@SFV099C48], [@SFV099C67]\].

Types and durations of interventions {#s3c}
------------------------------------

The intervention was based on aerobic exercise in 44 studies \[[@SFV099C9]--[@SFV099C12], [@SFV099C16], [@SFV099C17], [@SFV099C21]--[@SFV099C24], [@SFV099C26], [@SFV099C29], [@SFV099C30], [@SFV099C32], [@SFV099C33], [@SFV099C35]--[@SFV099C37], [@SFV099C39], [@SFV099C42]--[@SFV099C46], [@SFV099C48]--[@SFV099C51], [@SFV099C53], [@SFV099C56]--[@SFV099C58], [@SFV099C60]--[@SFV099C63], [@SFV099C65], [@SFV099C66]\], lasting from 30 to 90 min per session, with intensities ranging from 60 to 80% of maximal oxygen consumption (VO~2~ max). Resistance exercises were used in nine studies \[[@SFV099C8], [@SFV099C13]--[@SFV099C15], [@SFV099C20], [@SFV099C55], [@SFV099C56], [@SFV099C64]\], two were associated with nutrition \[[@SFV099C13], [@SFV099C20]\] and nine combined aerobic and resistance exercises \[[@SFV099C18], [@SFV099C31], [@SFV099C34], [@SFV099C36], [@SFV099C38], [@SFV099C47], [@SFV099C50], [@SFV099C54], [@SFV099C59]\]. One study applied as intervention intradialytic electromyostimulation of leg extensors \[[@SFV099C19]\]. Two RCTs \[[@SFV099C25], [@SFV099C64]\] compared drug treatment with exercise, with one of them including only CKD patients with restless legs \[[@SFV099C25]\]. Gordon *et al.* \[[@SFV099C27]\] and Yurtkuran *et al.* \[[@SFV099C17]\] used yoga-based exercise. Most studies used intradialytic exercise two to three times a week. Supervised exercise interventions were used in the most studies; one study used physical activity advice alone \[[@SFV099C22]\].

### Outcomes measures {#s3c1}

*Health-related quality of life (HRQOL)*: HRQOL was analyzed in 21 studies \[[@SFV099C18], [@SFV099C19], [@SFV099C22], [@SFV099C32], [@SFV099C40], [@SFV099C43], [@SFV099C45]--[@SFV099C50], [@SFV099C55], [@SFV099C59], [@SFV099C64], [@SFV099C67], [@SFV099C70]\]. Five studies found improvements in only the Physical Component Score \[[@SFV099C32], [@SFV099C45], [@SFV099C47], [@SFV099C48], [@SFV099C64]\], with ∼10% higher scores in the exercise groups. The 36-item Short Form Health Survey (SF-36) \[[@SFV099C12], [@SFV099C15], [@SFV099C18], [@SFV099C23], [@SFV099C32], [@SFV099C40], [@SFV099C43], [@SFV099C67]\] was the instrument most frequently used. Only two studies used a disease-specific instrument, the Kidney Disease Quality of Life (KDQOL) \[[@SFV099C40], [@SFV099C50]\]. The Quality of Life Index \[[@SFV099C47]\], Scale of Life Satisfaction \[[@SFV099C63]\] and Sleep Quality \[[@SFV099C24]\] were each used once.

*Physical fitness*: Measures of physical fitness, such as oxygen peak consumption (VO~2~ peak) were assessed in 20 aerobic interventions \[[@SFV099C9], [@SFV099C12], [@SFV099C16], [@SFV099C21], [@SFV099C29]--[@SFV099C32], [@SFV099C35]--[@SFV099C37], [@SFV099C39], [@SFV099C47], [@SFV099C48], [@SFV099C51], [@SFV099C53], [@SFV099C58], [@SFV099C61]--[@SFV099C63]\]. On average, aerobic exercise lasting from 8 weeks to 6 months improved VO~2~ peak ∼20%, from 8.2% \[[@SFV099C30]\] to 43% \[[@SFV099C61], [@SFV099C62]\].

*Heart rate variability (HRV)*: Seven studies evaluated the effect of exercise on HRV \[[@SFV099C16], [@SFV099C29], [@SFV099C36], [@SFV099C37], [@SFV099C51], [@SFV099C52], [@SFV099C63]\]: five in hemodialysis, one in kidney transplant patients \[[@SFV099C37]\] and one pre-dialysis \[[@SFV099C29]\]. Only the study by Reboredo *et al.* \[[@SFV099C52]\] found no difference in HRV. When HRV was assessed in the time domain, the outcome measures were SDNN and HRV index.

*Lipid profile*: Most studies including lipid profiles \[[@SFV099C8], [@SFV099C15], [@SFV099C17], [@SFV099C20], [@SFV099C21], [@SFV099C26], [@SFV099C29], [@SFV099C39], [@SFV099C45], [@SFV099C56], [@SFV099C59], [@SFV099C60]\] as an outcome measure found no effect of the exercise intervention on LDL cholesterol, HDL cholesterol or triglycerides, with the exception of one study that used yoga as the intervention, which reported a 15% decrease in lipids after a 12-week follow-up \[[@SFV099C17]\].

*Inflammatory markers*: Inflammatory biomarkers such as C-reactive protein (CRP) and interleukins were evaluated in 10 studies \[[@SFV099C8], [@SFV099C13]--[@SFV099C15], [@SFV099C29], [@SFV099C30], [@SFV099C34], [@SFV099C39], [@SFV099C50], [@SFV099C60]\]; in general, a positive effect of exercise interventions was detected for such outcomes. Compared with the control group, a significant reduction of CRP (P = 0.005 and P = 0.036) was demonstrated in aerobic and resistance training groups in the Afshar *et al.* study \[[@SFV099C8]\]. In another study \[[@SFV099C15]\], high-intensity resistance training decreased CRP, with a risk reduction (RR) of −0.63 (95% CI −0.54--0.00). Castaneda *et al.* \[[@SFV099C14]\] also applied resistance training, which decreased CRP 1.7 mg/L (P = 0.01), with no change in the control group. Kopple *et al.* \[[@SFV099C34]\] compared the effect of different forms of exercise training (endurance, strength or combination), and found no change in serum CRP with exercise training or in the control group.

*Muscular strength*: Nine RCTs whose intervention was resistance training \[[@SFV099C8], [@SFV099C13]--[@SFV099C15], [@SFV099C20], [@SFV099C32], [@SFV099C55], [@SFV099C56], [@SFV099C67]\] or aerobic and resistance training \[[@SFV099C8], [@SFV099C54], [@SFV099C59]\] measured muscular strength as one of their outcome measures, two in pre-dialysis patients \[[@SFV099C11], [@SFV099C14]\], another in kidney transplant patients \[[@SFV099C32]\] and the remaining in hemodialysis patients. One study using aerobic and muscle electrostimulation \[[@SFV099C19]\] and an other with yoga \[[@SFV099C17]\] also measured the effects on muscular strength. All of these found an increase in strength after intervention. Mallamaci *et al.* \[[@SFV099C42]\] assessed lower limb strength in patients on hemodialysis, and scores on the sit-to-stand test increased from 18.3 ± 5.1 to 19.7 ± 6.7 (P = 0.009) in the intervention group compared with the control group. In pre-dialysis patients \[[@SFV099C11], [@SFV099C14], [@SFV099C54]\], the intervention group improved ∼28% (P \< 0.001) for muscular strength, as in kidney transplant patients \[[@SFV099C32]\]. Dobsak *et al.* \[[@SFV099C19]\] applied aerobic exercise (AT) or muscle electrostimulation (EMS) and muscle power increased with EMS to 222.2 ± 36.6 (P = 0.046) and with AT to 230.3 ± 31.1 (P = 0.033), while the control group remained at 187.8 ± 29.7. The yoga-based study found an improvement of 15% in muscular strength \[[@SFV099C17]\].

*Body composition*: Six studies analyzed the effects of resistance exercise on body composition. Four studied hemodialysis patients \[[@SFV099C15], [@SFV099C20], [@SFV099C64], [@SFV099C67]\] and one analyzed kidney transplant patients \[[@SFV099C32]\]. Resistance exercise did not change body composition. One RCT analyzed the effect of exercise in obese pre-dialysis patients \[[@SFV099C10]\] and found a visceral fat and waist circumference decrease of 6.4 ± 6.4 mm (P \< 0.01) and 2.0 ± 2.3 cm (P = 0.03) and leg lean mass increased 0.5 ± 0.4 kg (P \< 0.01).

*CKD progression*: The effect of aerobic \[[@SFV099C21], [@SFV099C29]--[@SFV099C31], [@SFV099C39]\] or resistance \[[@SFV099C13], [@SFV099C31]\] training on CKD progression was measured in four RCTs. A slower decline in the rate of change in glomerular filtration was found in one study in patients randomized to a low protein diet and resistance training \[[@SFV099C13]\].

*PWV and arterial stiffness*: Two studies measured PWV in pre-dialysis \[[@SFV099C30], [@SFV099C31]\] patients and found no effect of exercise. Toussant *et al.* \[[@SFV099C57]\] studied hemodialysis patients and found a positive effect of aerobic exercise (9.04±0.59 versus 10.16±0.74, P = 0.008), but Koh *et al.* \[[@SFV099C65]\] did not find a difference between intradialytic exercise or usual care.

*Depression*: Depression was analyzed in four RCTs, three of them using aerobic exercise \[[@SFV099C12], [@SFV099C24], [@SFV099C63]\] and one aerobic plus resistance exercise \[[@SFV099C47]\]. Exercise decreased depression scores. The Beck Depression Index decreased 34.5% in the Kouidi *et al.* trial \[[@SFV099C63]\] and 39.4% in Ozouni *et al.* trial \[[@SFV099C47]\], as occurred in the study by Ginakki *et al.* \[[@SFV099C24]\] (P = 0.002). Only Carmack *et al.* \[[@SFV099C12]\] was unable to find a benefit of exercise on depression.

*CKD stage and type of treatment*: Forty-five \[[@SFV099C8], [@SFV099C9], [@SFV099C11], [@SFV099C12], [@SFV099C15]--[@SFV099C20], [@SFV099C23]--[@SFV099C27], [@SFV099C34]--[@SFV099C38], [@SFV099C40], [@SFV099C41], [@SFV099C43]--[@SFV099C53], [@SFV099C55]--[@SFV099C62], [@SFV099C64], [@SFV099C67], [@SFV099C70]\] of 59 studies were carried out in ESRD patients on hemodialysis. Only one study included both hemodialysis and peritoneal dialysis patients \[[@SFV099C35]\]. Five of these studies had CRP as an outcome measure; in three of them CRP was inversely correlated with physical activity \[[@SFV099C8], [@SFV099C15], [@SFV099C50]\] and another found no change \[[@SFV099C34], [@SFV099C39], [@SFV099C60]\]. Fourteen studies assessed VO~2~ peak and all of them found a significant increase with aerobic exercise \[[@SFV099C29]--[@SFV099C31], [@SFV099C36], [@SFV099C37], [@SFV099C47], [@SFV099C48], [@SFV099C51], [@SFV099C53], [@SFV099C62], [@SFV099C63]\]. Strength was measured in nine resistance studies \[[@SFV099C15], [@SFV099C18], [@SFV099C20], [@SFV099C32], [@SFV099C55], [@SFV099C56], [@SFV099C59], [@SFV099C67]\], all of them with a positive finding. HRQOL was assessed in 18 studies \[[@SFV099C15], [@SFV099C18], [@SFV099C19], [@SFV099C22], [@SFV099C40], [@SFV099C43], [@SFV099C45], [@SFV099C47]--[@SFV099C50], [@SFV099C55], [@SFV099C56], [@SFV099C59], [@SFV099C64], [@SFV099C67], [@SFV099C70]\]; 11 of them found increases in HRQOL in the exercise groups, both in aerobic and resistance training \[[@SFV099C22], [@SFV099C40], [@SFV099C43], [@SFV099C45], [@SFV099C47], [@SFV099C48], [@SFV099C50], [@SFV099C56], [@SFV099C59], [@SFV099C64]\]. However, four of these studies found improvements only in the physical component of the HRQOL \[[@SFV099C45], [@SFV099C47], [@SFV099C48], [@SFV099C64]\].

*Pre-dialysis*: Eleven studies \[[@SFV099C10], [@SFV099C13], [@SFV099C14], [@SFV099C21], [@SFV099C22], [@SFV099C28]--[@SFV099C31], [@SFV099C39], [@SFV099C54]\] included pre-dialysis patients; one study enrolled patients on dialysis and pre-dialysis \[[@SFV099C39]\]. The studies that included pre-dialysis patients actually reported findings from eight different interventions, because one study generated two different publications \[[@SFV099C13], [@SFV099C14]\]. Three studies used CRP as an outcome measure \[[@SFV099C14], [@SFV099C30], [@SFV099C39]\], of which only one found a positive association between exercise and decreased CRP \[[@SFV099C14]\]. Six studies \[[@SFV099C13], [@SFV099C21], [@SFV099C29]--[@SFV099C31],[@SFV099C39]\] evaluated the progression of CKD, and only Castaneda *et al.* \[[@SFV099C13]\] found a significant positive effect of the exercise intervention on this outcome. Physical capacity was assessed through VO~2~ peak in five studies \[[@SFV099C21], [@SFV099C28]--[@SFV099C31]\], all of them with positive results. Three publications \[[@SFV099C13], [@SFV099C14], [@SFV099C31]\] used resistance training, two of them using the same study \[[@SFV099C13], [@SFV099C14]\], and in another \[[@SFV099C30]\] the training was associated with lifestyle interventions. HRQOL was measured in two studies \[[@SFV099C22], [@SFV099C30]\], one of them \[[@SFV099C22]\] included pre-dialysis and dialysis patients, and both found improved HRQOL after exercise.

*Kidney transplantation*: Three RCTs \[[@SFV099C32], [@SFV099C33], [@SFV099C37]\] assessing exercise in kidney transplant patients were found, all of them using aerobic training interventions. The outcome measures were VO~2~ peak, analyzed in two studies \[[@SFV099C32], [@SFV099C37]\], which increased 16--20%. HRV was analyzed in Koudi *et al*. \[[@SFV099C37]\], with positive findings as well. One of them found no difference in HRQOL with exercise \[[@SFV099C32]\] and another found increases in HDL cholesterol in the exercise group \[[@SFV099C33]\].

Discussion {#s4}
==========

This systematic review gathered consistent evidence of the positive effects of aerobic exercise on physical fitness, muscular strength and quality of life in ESRD patients. The evidence regarding exercise effects on other health outcomes and/or in earlier stages of CKD are weaker and heterogeneous.

The improvement in fitness through exercise in ESRD patients is a noteworthy finding. Functional capacity is usually impaired in CKD patients, reaching ∼60--65% of the age-predicted value \[[@SFV099C71]\]. This low level of fitness is worrisome considering its association with poorer HRQOL \[[@SFV099C32], [@SFV099C48]\] and higher mortality in CKD patients \[[@SFV099C72]\].

Exercise requires the integrated function of multiple vital organs. Low exercise capacity is also an independent predictor of mortality in other chronic disease populations. Since physical training can improve functional capacity, maybe it can also increase survival. Although there is no RCT up to now confirming this hypothesis, the Dialysis Morbidity and Mortality Study, a cohort study, found that dialysis patients engaged in more frequent exercise presented a significantly reduced mortality rate versus less active peers \[[@SFV099C73]\].

Patients on dialysis are also weaker when compared with healthy sedentary subjects, and weakness may contribute to their poor physical functioning. Muscular strength has been described as a significant predictor of gait speed \[[@SFV099C73]\] and VO~2~ peak \[[@SFV099C73]\] in dialysis patients.

The findings of our systematic review are in accordance with those of Heiwe and Jacobsen, whose meta-analysis for the Cochrane Collaboration was published in 2011 \[[@SFV099C74]\] and updated in 2014 \[[@SFV099C75]\]. They found significant beneficial effects of various exercise interventions in CKD patients on physical fitness, muscular functioning, walking capacity, cardiovascular function and HRQOL, with stronger evidence for dialysis patients and aerobic exercise programs.

Our finding about HRV is also interesting. Although there are few RCTs on the issue, six of the seven studies assessing HRV included in this review found significant improvement in this variable after exercise \[[@SFV099C16], [@SFV099C29], [@SFV099C36], [@SFV099C37], [@SFV099C51], [@SFV099C63]\]. The association between CKD and low HRV is consistent across multiple stages of the disease, including micro- and macro-albuminuria, decreased estimated glomerular filtration rate (eGFR) and ESRD \[[@SFV099C76]\]. In addition to CKD, other risk factors for low HRV include older age, obesity, diabetes, sedentary lifestyle, low HDL cholesterol, high insulin levels, elevated CRP and high systolic blood pressure \[[@SFV099C76]\]. Some studies \[[@SFV099C76]\] have shown that elevated resting heart rate and low HRV are associated with an increased risk of ESRD, CKD-related hospitalization and arrhythmias.

The Cochrane meta-analysis also found that the HRV index significantly improved after 6 months of mixed aerobic and resistance training in hemodialysis patients \[[@SFV099C74], [@SFV099C75]\]. The United Kingdom Heart Failure Evaluation and Assessment of Risk Trial (UK-Heart) \[[@SFV099C77]\] recently found that the SDNN, an HRV index, \<100 ms was associated with increased mortality. The impact of HRV on mortality might be explained by the sympathetic/parasympathetic balance, with sympathetic nervous system overactivation in patients with lower HRV, which led to an increased susceptibility to malignant arrhythmia \[[@SFV099C78]\].

Considering that exercise improves HRV in hemodialysis patients, and that arrhythmia is one of the major causes of CV mortality in this subset of patients \[[@SFV099C79]\], we might expect a positive effect of exercise on mortality in hemodialysis patients. However, to date, only one study analyzed the effect of high-intensity mixed aerobic and resistance training in hemodialysis patients on arrhythmias and found no difference between the intervention and control groups \[[@SFV099C36]\].

Despite the auspicious findings, this systematic review has some limitations. The RCTs included present moderate to low quality and high risk of bias. Assessment of the quality of trial randomization, the avoidance of exclusions after trial entry and blinding have been proposed as the most important methodological components of controlled trials \[[@SFV099C80]\].

First, during the preparation of this review, a large number of exercise trials were excluded because no randomization of participants had been done. Allocation concealment also seems to be a significant issue. Inadequate concealment can lead to bias in many ways, sometimes as the result of deliberate subversions (usually well intentioned), or as the result of subconscious actions. Trials that reported either inadequate or unclear concealment methods yielded estimates of odds ratios that were exaggerated by an average of 41 or 30%, respectively, compared with estimates of odds ratios derived from trials that apparently had taken adequate steps to conceal treatment allocation \[[@SFV099C81]\]. Only 14 studies included in this review reported allocation concealment \[[@SFV099C11], [@SFV099C15], [@SFV099C17], [@SFV099C18], [@SFV099C25], [@SFV099C31]--[@SFV099C33], [@SFV099C35]--[@SFV099C37], [@SFV099C45], [@SFV099C55], [@SFV099C65]\]. Furthermore, most of them did not analyze data according to the intention-to-treat principle, thus increasing the risk of selection bias. Not using intention-to-treat analysis might have inflated the apparent results. Moreover, there were deficiencies in the reporting of methodological information and findings, such as method of randomization, dropout rate, adherence to the intervention and controls. Readers of the present study should be aware that it is possible that a trial could have been classified as having lower quality than it truly had because data and/or information were missing. Despite the availability of guidelines aimed at standardizing the reporting of clinical trials, publications often omit essential methodological details.

In addition to methodological and reporting problems with the current literature about the effects of exercise on health of ESRD, we detected the scarcity of trials including patients in earlier stages of CKD.

From a public health standpoint, the fact that most studies included only hemodialysis patients represents a point of concern, because patients as well as health systems would most benefit from primary prevention or from interventions that increase survival and/or delay the need for RRT in earlier stages of CKD, whose population is ∼20 times greater than the ESRD population. The need for RCTs in pre-dialysis patients is amplified by positive findings from observational studies in CKD stages II--IV showing the association of higher physical activity with slower rates of glomerular filtration decline \[[@SFV099C82]\] and higher survival rates \[[@SFV099C72]\]. If could be confirmed that exercise interventions are effective in delaying CKD progression and/or decrease mortality, the potential impact of such interventions for public health would be enormous.

Despite the lack of RCT-based evidence about the effect of exercise on mortality, the already documented effects of exercise on physical function, strength, quality of life and cardiovascular index, such as HRV, are enough to support the recommendation of moderate-intensity physical activity for CKD patients. Exercise interventions need to be progressively included in the regimens of hemodialysis centers, aiming for inclusion in all dialysis centers, even though the best exercise protocol for dialysis patients remains to be established.
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[^1]: I, intervention group; C, control group; P-HD, pre-HD; HD, hemodialysis; Tx, renal transplantation; HRV, heart rate variability; SDNN, standard deviation of normal-to-normal intervals; HF, marker of vagal activity; LF, parameter that includes both sympathetic and vagal influences; ratio LF/HF, marker of sympathovagal balance; RPE, rating of perceived exertion; CRP, C-reactive protein; 6MWT, 6-minute walk test; CSA, cross-sectional area; VO~2~AT, anerobic threshold; VO~2~ max, maximal oxygen consumption; eGFR, estimated glomerular filtration rate; TBP, total body potassium; SPPB, Short Physical Performance Battery; RLS, restless leg syndrome; LBM, lean body mass; PWV, pulse wave velocity; RMT, respiratory muscle training; PMT, peripheral muscle training; PI(max), maximal inspiratory pressure; PE(max), maximal expiratory pressure; FVC, forced vital capacity; URR, urea reduction ratio; STS, sit-to-stand; Wpeak, peak workload; DUC, dialysate urea clearance; OS, oxidative stress; IL-6, interleukin 6; K, potassium; P, phosphorus; Ca, calcium; ALP, alkaline phosphatase.
